Navigation Links
Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008
Date:11/3/2009

, regulatory filings and actions and Onyx's anticipated acquisition of Proteolix, Inc. and its lead product candidate, carfilzomib. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: Nexavar being our only approved product; competition; failures or delays in our clinical trials; dependence on our collaborative relationship with Bayer; market acceptance and the rate of adoption of our products; pharmaceutical pricing and reimbursement pressures; serious adverse side effects, if they are associated with Nexavar; government regulation; possible failure to realize the anticipated benefits of business acquisitions or strategic investments; protection of our intellectual property; the indebtedness incurred through the sale of our 4.0% convertible senior notes due 2016; product liability risks; and the consummation and anticipated benefits of the proposed acquisition of Proteolix. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2008, filed with the Securities and Exchange Commission, under the heading "Risk Factors" for a more detailed description of these and other risks, as well as the company's subsequent quarterly reports on Form 10Q. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

                           (See attached tables.)


                        ONYX PHARMACEUTICALS, INC.
                    CONDENSED STATEMENTS OF OPERATIONS
                 (In thousands, except per share amounts)
                                (unaudited)

                    
'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
2. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
3. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
4. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
5. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
6. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
7. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
8. DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America
9. Peregrine Pharmaceuticals Announces Implementation of 1:5 Reverse Stock Split to Take Effect October 19, 2009
10. Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
11. Amira Pharmaceuticals to Present at Montgomery Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... Philadelphia (PRWEB) , ... September ... ... global provider of high-quality patient safety and efficacy endpoint data collection, cloud ... Annual European PRO and eCOA Congress in Lisbon, Portugal, September 22-24, 2015. ...
(Date:9/3/2015)... ... September 03, 2015 , ... “Love in Tokyo” an independent ... Play , and Amazon and will be released on DVD early next ... is a Foreigner,” Itsuka, an actress and singer/songwriter, and Jason London, lead from “Dazed ...
(Date:9/3/2015)... ... , ... When looking at the types of people who have a hard time gaining ... have a weak appetite or those that have a fast metabolism. In order to help ... Gainer gives three tips for slowing down metabolism. , The first thing to do is ...
(Date:9/3/2015)... ... September 03, 2015 , ... Doctor Kayode Sotonwa can be counted ... there. His perspective on internal medicine keeps patients happy and healthy, something that is ... regardless of the season, but even more so in the fall, when holiday eating ...
(Date:9/2/2015)... ... 2015 , ... One can hardly argue against the fact that more and ... personal computers. These devices are being used as GPS, to make purchases, and yes, ... apps, STD positive singles can now join the prestigious social ranks of e-dating. ...
Breaking Medicine News(10 mins):Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 3Health News:The Romantic Comedy Film "Love in Tokyo" Has Been Released on ITunes, Google Play, and Amazon 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3Health News:Doctor Kayode Sotonwa Highlights Expert Tips for Staying in Shape This Fall 2Health News:Herpes-datingsites.com Recently Added Reviews of 5 STD Dating Apps for STD Positive Singles 2
... Needs of Life Science Companies, Health Care ProvidersLIBERTYVILLE, ... a leader in digital sales and marketing solutions, ... the nation,s leading provider of online, on-demand prescription ... a wholly owned subsidiary of Physicians Interactive LLC. ...
... Alliance Creates the Nation,s Largest Independent Online Retailer ... Million CustomersNEW YORK, March 24 Sandow Media, ... e-commerce Web site SpaLook.com, and Salu Beauty, parent ... deliver unprecedented scale and reach for beauty product ...
... Gather to Discuss Interactive Patient Care, Patient Engagement ... GetWellNetwork, Inc., the leading provider of ... highly successful conference, GetConnected2009 . ... GetConnected2009 is the industry,s leading annual ...
... Month , HARRISBURG, Pa., April 1 The Department ... for men and women to take steps to prevent ... well as the importance of discussing their sexual health ... are treatable, screening and early diagnosis are essential to ...
... at 5:00 p.m. EDT -- SOUTH SAN FRANCISCO, ... SNSS ) today announced the execution of a ... private placement of up to $43.5 million in a ... convertible preferred stock and common stock warrants, and a ...
... Medical Innovations, Inc. (NYSE: IMA ), a global ... at home through the merger of rapid diagnostics and health ... was elected to the company,s board of directors. Dr. Adashi, ... Care and in the Life Sciences was also appointed to ...
Cached Medicine News:Health News:Physicians Interactive Acquires MedManage Systems 2Health News:Physicians Interactive Acquires MedManage Systems 3Health News:NewBeauty Magazine and SpaLook.com Create Strategic Alliance With Salu Beauty and SkinStore.com 2Health News:NewBeauty Magazine and SpaLook.com Create Strategic Alliance With Salu Beauty and SkinStore.com 3Health News:Innovation and Sharing of Client Successes Highlight GetWellNetwork's GetConnected2009 Conference 2Health News:Innovation and Sharing of Client Successes Highlight GetWellNetwork's GetConnected2009 Conference 3Health News:Innovation and Sharing of Client Successes Highlight GetWellNetwork's GetConnected2009 Conference 4Health News:Pennsylvania Department of Health Urges Greater Awareness of, Testing for Sexually Transmitted Diseases 2Health News:Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing 2Health News:Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing 3Health News:Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing 4Health News:Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing 5Health News:Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing 6Health News:Eli Y. Adashi, MD, MS, FACOG, Joins Inverness Medical Innovations' Board of Directors 2
(Date:9/2/2015)...   About ELISA test ELISA test ... is used for measuring the concentration of analytes such ... various types of enzymes such as carbonic anhydrase, glucose ... by photometry or fluorometry. ELISA is used as a ... such as HIV, pernicious anemia, rotavirus, Rocky Mountain spotted ...
(Date:9/2/2015)... 2015 STAAR Surgical Company (NASDAQ: STAA ), ... delivery systems for the eye, today announced that its Board ... the Company,s Board. Mr. Wall was formerly ... -based investment firm, for more than nine years. Mr. ... and chair of the Corporate Governance Committee and member of ...
(Date:9/2/2015)... , Sept. 2, 2015 Research and ... the "Inhaled Drug Delivery (London, UK - November ... This Inhaled Drug Delivery meeting will cover industry case ... much more. The Co-Chairmen are Dr Steven Nichols ... Senior Director, Mylan. Companies participating include: ...
Breaking Medicine Technology:Global Enzyme-Linked Immunosorbent Assay (Elisa) Testing Market 2015-2019 2Global Enzyme-Linked Immunosorbent Assay (Elisa) Testing Market 2015-2019 3William P. Wall Appointed to STAAR Surgical Board of Directors 2
... NEW YORK, Dec. 13, 2010 Pfizer Inc. (NYSE: ... Directors has elected George A. Lorch, 68, who has served ... the Board, effective immediately. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) ... said, "George Lorch has been a valuable, independent voice on ...
... Company announced today that it has suspended its global ... compound, as a second-line treatment for those with unresectable ... with an independent data monitoring committee, recommended a "full ... hold ensures that no new or existing patients in ...
Cached Medicine Technology:Pfizer Board of Directors Elects George A. Lorch Non-Executive Chairman 2Lilly Suspends Phase III Trial in Metastatic Melanoma 2Lilly Suspends Phase III Trial in Metastatic Melanoma 3
Urea nitrogen (BUN) liquid reagent is used for the kinetic quantitative determination of Urea Nitrogen (BUN) in human serum used in routine examination and monitoring of therapy and relapses....
Intended for the quantitative determination of urea nitrogen in serum. Reaction: kinetic. Wavelength: 340 nm. Linearity: 150 mg/dL (53.4 mmol/L urea) at 37C....
Intended for the quantitative determination of direct bilirubin in serum. Modified EvelynMalloy Method. Endpoint Reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... microplate spectrophotometer designed specifically to run 24 ... With rugged hardware, proven optical performance and ... of traditional spectrophotometry to obtain results quickly, ... read up to eight, 1 cm Biocell ...
Medicine Products: